Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer

Journal of Clinical Oncology

Volumn 25, Issue 34, 2007, Pages 5359-5365

  Shahinian, Vahakn B ^a   Kuo, Yong Fang ^a   Freeman, Jean L ^a   Orihuela, Eduardo ^a   Goodwin, James S ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SCHOOL; MEDICAL SOCIETY; ORCHIECTOMY; PATIENT CARE; PHYSICIAN; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; VOCATIONAL EDUCATION;

ADULT; AGED; ANDROGEN ANTAGONISTS; ANDROGENS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UROLOGY;

EID: 36849073090     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.9580     Document Type: Article

References (38)

1. Shahinian VB, Kuo Y-F, Freeman JL, et al: Increasing use of gonadotropin-releasing hormone agonists for localized prostate cancer. Cancer 103:1615-1624, 2005
2. Meng MV, Grossfeld GD, Sadetsky N, et al: Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology 60:7-11, 2002 (3 suppl 1)
3. Fellows GJ, Clark PB, Beynon LL, et al: Treatment of advanced localized prostatic cancer by orchiectomy, radiotherapy, or combined treatment: A Medical Research Council study - Urological cancer working party-subgroup on prostatic cancer. Br J Urol 70:304-309, 1992
4. Bolla M, Gonzalez D, Warde P, et al: Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer: Results of a randomized phase III clinical trial of the EORTC radiotherapy and genitourinary tract cancer cooperative groups. Proc Am Soc Clin Oncol 15:238, 1995 (abstr 591)
5. Baker LH, Hanks G, Gershenson D, et al: NCCN prostate cancer practice guidelines: The National Comprehensive Cancer Network. Oncology (Williston Park) 10:265-288, 1996 (11 suppl)
6. Chodak GW, Keane T, Klotz L: The Hormone Therapy Study Group: Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60:201-208, 2002
7. Middleton RG: The management of clinically localized prostate cancer: Guidelines from the American Urological Association. CA Cancer J Clin 46:249-253, 1996
8. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004
9. Holzbeierlein JM, McLaughlin MD, Thrasher JB: Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 14:177-183, 2004
10. Part B Physician/Supplier National Data, CY 2003. Top 200 Level II Health Care Common Procedure Coding System Codes. http://www.cms.hhs.gov/ MedicareFeeforSvcPartsAB/Downloads/LEVEL2Charg03.pdf
11. Cooperberg MR, Grossfeld GD, Lubeck DP, et al: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 95:981-989, 2003
12. Potosky AL, Knopf K, Clegg LX, et al: Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study. J Clin Oncol 19:3750-3757, 2001
13. Wennberg J, Gittelsohn A: Variations in medical care among small areas. Sci Am 246:120-134, 1982
14. Shahinian VB, Kuo YF, Freeman JL, et al: Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist. J Natl Cancer Inst 98:839-845, 2006
15. Warren JL, Klabunde CN, Schrag D, et al: Overview of the SEER-medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:3-18, 2002 (suppl IV)
16. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
17. SEER-Medicare: Provider files. http://healthservices.cancer.gov/ seermedicare/aboutdata/provider.html
18. Baldwin L-M, Adamache E, Klabunde CN, et al: Linking physician characteristics and medicare claims data: Issues in data availability, quality and measurement. Med Care 40:82-95, 2002 (suppl IV)
19. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
20. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
21. Welch HG, Albertsen PC, Nease RF, et al: Estimating treatment benefits for the elderly: The effect of competing risks. Ann Intern Med 124:577-584, 1996
22. Shahinian VB, Kuo Y-F, Freeman JL, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005
23. Fritz A, Ries L: Surveillance, Epidemiology, and End Results (SEER): Extent of disease: Codes and coding instructions, 1988 (ed 3). Bethesda, MD, US Department of Health and Human Services, Public Health Services, National Institutes of Health, 1998
24. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
25. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
26. Donini-Lenhoff F (ed): Guidebook for GME program directors. Chicago, IL, American Medical Association, 2005, p 59
27. Allison PD: Missing Data. Thousand Oaks, CA, Sage Publications, 2001, pp 50-74
28. Warren JL, Harlan LC, Fahey A, et al: Utility of the Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify chemotherapy use. Med Care 40:55-61, 2002 (suppl IV)
29. Raudenbush SW, Bryk AS: Hierarchical linear models: Applications and data analysis methods (ed 2). Thousand Oaks, CA, Sage, 2002
30. Leyland AH, Goldstein H: Multilevel Modeling of Health Statistics. West Sussex, England, John Wiley and Sons, Ltd, 2001
31. Artis LC, Burkhart TM, Johnson TJ, et al: Physician factors as an indicator of technological device adoption. J Med Syst 30:177-186, 2006
32. Voss JD, Schectman JM: Prostate cancer screening practices and beliefs: A longitudinal physician survey. J Gen Intern Med 16:831-837, 2001
33. General Accounting Office Report: Medicare: Payments for Covered Outpatient Drugs Exceed Providers' Costs. http://www.gao.gov/new.items/d011118. pdf
34. Scionti SM: Medicare reform: A major economic impact on urological practice. Business Briefing: US Kidney & Urological Disease 2005. http://www.touchbriefings.com/cdps/cditem.cfm?cid=5&nid=1322
35. Ting JYS: Letter to the editor. JAMA 295:2846, 2006
36. Winn RJ: The role of oncology clinical practice guidelines in the managed care era. Oncology (Williston Park) 9:177-183, 1995
37. Ryan CJ, Small EJ: Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 23:8225-8231, 2005
38. Bhandari MS, Crook J, Hussain M: Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 23:8212-8218, 2005